Clinical Trial Update: HP184 in Chronic Spinal Cord Injury Subjects [Phase 2]

View source ↗

Summary

Sanofi announced the completion of a Phase 2 trial evaluating HP184 in chronic spinal cord injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• HP184

Snippet

Sponsor: Sanofi | Conditions: Spinal Cord Injury | Phase 2 | Status: COMPLETED